Summary
Latest filing:
Jonathan Goldman files SEC Form 4 reports at Avalo Therapeutics, Inc. (AVTX). 2 SEC Form 4 filings on record going back to 2025, most recently on 31 March 2026. Most recent open-market trade: sold $118K of AVTX on 17 November 2025. Lifetime open-market sales: $163K.
Recent Transactions
4Every recent SEC Form 4 transaction Jonathan Goldman has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Jonathan Goldman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Christopher Ryan Sullivan - $3.52M of AVTX open-market activity in the last 12 months
- Mittie Doyle - $2.98M of AVTX open-market activity in the last 12 months
- Paul Varki - $1.51M of AVTX open-market activity in the last 12 months
- Mitchell Chan - $72K of AVTX open-market activity in the last 12 months
- Jennifer Riley - $52K of AVTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Jonathan Goldman?
Jonathan Goldman is a corporate insider of Avalo Therapeutics, Inc. (AVTX). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Jonathan Goldman last file a Form 4?
The most recent primary Form 4 on record is dated 31 March 2026, one of 2 filings going back to 2025.
Has Jonathan Goldman been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($163K) across all tracked filings.
Where can I see all of Jonathan Goldman's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Jonathan Goldman and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
